Clinical Trial Year ClinicalStage LymphNodeStage EvaluatedTreatment AxillaryRelapse Residual axillarydisease OverallSurvivall
NSABP 04 (12) 1977 I cN0 LA 19% 40% No benefit
Ragaz Trial (13) 1997 II, III N1, N2, N3 RTP 22% vs 12% - 0,05
DBCG 82 (15) 1997 II, III N1, N2, N3 RTP 26% vs 5% - Benefit
Milan Trial (16) 2003 I N0 LA 0% 4,6% No benefit
NSABP 32 (17) 2007 I N0 LA 0,2% 9,8% No benefit
GIVOM Trial (18) 2008 I N0 LA 0,2% 7,3% -
ACOSOG Z0011 (14) 2010 I N1 LA 1,8% vs 3,6% 27,3% No benefit
AATRM 048/13/2000 (19) 2013 IB N1mic LA 2,5% vs 1% 13% No benefit
IBCSG 23-01 (20) 2013 IB N1mic LA 1% vs 0,2% 13% No benefit
AMAROS (21) 2014 II N1 LA vs RTP 0,5% vs 0,1 33% No benefit
MA20 (22) 2015 I, II, III N0, N1, N2 LA vs RTP 2,5% vs 0,5% - No benefit
EORTC 22922 (23) 2015 I, II, III N0, N1, N2, N3 RTP 1,9% vs 1,3% - No benefit
Table 1: Results of clinical trials that have examined axillary treatment impact on global and disease-free survival